Current investments

Receive information about upcoming investment opportunities

Sign up below to get information about upcoming investment opportunities and investor lunch meetings with the companies’ managements.

Completed investments

Sciety_Predicare-RETTS

Predicare

Predicare is the company behind the system RETTS©, used by 95% of Sweden’s hospitals and ambulances. RETTS© daily helps healthcare professionals to make the right decisions in emergency situations.

Read more

Single Technologies

The company has developed a DNA sequencing solution with significantly improved performance compared with current alternatives. The market is growing rapidly in terms of both research and clinical applications.

Read more

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more
Sciety_Cartana_NeuroKits

Cartana

Cartana’s patent-applied research tool revolutionises the possibility of analysing tissue samples, providing pharmaceutical companies with important information in their quest for new treatments.

Read more

Exits

Inhalation Sciences

Inhalation Sciences’ technology is used by prominent players within the chemical and pharma sectors to study how airborne particles impact the human body.

Read more

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Read more

Raytelligence

Raytelligence has developed a unique, non-intrusive radar sensor and cloud platform for monitoring vital signs, such as respiration, heartbeat and position and movement. The company is aimed at elderly care in the home.

Read more

Liv Diagnostics

Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.

Read more